Titel

Merkliste
1 Ergebnisse

Supplemental Table 1 from Phase II Study of the Liposomal F..:

Makoto Nishio ; Shuji Murakami ; Hisato Kawakami...
https://figshare.com/articles/journal_contribution/Supplemental_Table_1_from_Phase_II_Study_of_the_Liposomal_Formulation_of_Eribulin_E7389-LF_in_Combination_with_Nivolumab_Results_from_the_Small_Cell_Lung_Cancer_Cohort/25103047. , 2024

Link: https://doi.org/10.1158/2767-9764.25103047.v1

RT Journal
T1 <Title>Supplemental Table 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftsmithonianinsp:oai:figshare.com:article_25103047&Exemplar=1&LAN=DE
				
A1 Makoto Nishio
A1 Shuji Murakami
A1 Hisato Kawakami
A1 Kyoichi Okishio
A1 Motohiro Tamiya
A1 Haruki Kobayashi
A1 Daichi Fujimoto
A1 Shunichi Sugawara
A1 Toshiyuki Kozuki
A1 Yuko Oya
A1 Hiroki Izumi
A1 Takayuki Shiroyama
A1 Miyako Satouchi
A1 Noboru Yamamoto
A1 Shota Kaname
A1 Daiko Matsuoka
A1 Yohei Otake
A1 Takao Takase
A1 Taro Semba
A1 Koichi Azuma
YR 2024
K1 Cancer
K1 Immuno-oncology
K1 Clinical Research and Trials
K1 Lung Cancer
K1 Clinical Trial Results
K1 Phase II clinical trials
K1 Immunotherapy
K1 Checkpoint blockade
K1 Combination immunotherapy
JF https://figshare.com/articles/journal_contribution/Supplemental_Table_1_from_Phase_II_Study_of_the_Liposomal_Formulation_of_Eribulin_E7389-LF_in_Combination_with_Nivolumab_Results_from_the_Small_Cell_Lung_Cancer_Cohort/25103047
LK http://dx.doi.org/https://doi.org/10.1158/2767-9764.25103047.v1
DO https://doi.org/10.1158/2767-9764.25103047.v1
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)